JPH0321558B2 - - Google Patents
Info
- Publication number
- JPH0321558B2 JPH0321558B2 JP61051687A JP5168786A JPH0321558B2 JP H0321558 B2 JPH0321558 B2 JP H0321558B2 JP 61051687 A JP61051687 A JP 61051687A JP 5168786 A JP5168786 A JP 5168786A JP H0321558 B2 JPH0321558 B2 JP H0321558B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- lysozyme
- present
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000016943 Muramidase Human genes 0.000 claims description 15
- 108010014251 Muramidase Proteins 0.000 claims description 15
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 15
- 229960000274 lysozyme Drugs 0.000 claims description 15
- 239000004325 lysozyme Substances 0.000 claims description 15
- 235000010335 lysozyme Nutrition 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000008512 biological response Effects 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 239000003607 modifier Substances 0.000 claims description 3
- -1 organogermanium compound Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 150000002291 germanium compounds Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 15
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940093626 germanium sesquioxide Drugs 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000000082 organogermanium group Chemical group 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61051687A JPS62252793A (ja) | 1986-03-10 | 1986-03-10 | 有機ゲルマニウム化合物及びそれを含む薬剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61051687A JPS62252793A (ja) | 1986-03-10 | 1986-03-10 | 有機ゲルマニウム化合物及びそれを含む薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62252793A JPS62252793A (ja) | 1987-11-04 |
| JPH0321558B2 true JPH0321558B2 (de) | 1991-03-22 |
Family
ID=12893803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61051687A Granted JPS62252793A (ja) | 1986-03-10 | 1986-03-10 | 有機ゲルマニウム化合物及びそれを含む薬剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62252793A (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01139587A (ja) * | 1987-11-27 | 1989-06-01 | Sanwa Kagaku Kenkyusho Co Ltd | ３−オキシゲルミルプロピオン酸ポリマーの塩基性アミノ酸及び有機アミン塩、その製法及び該化合物を有効成分とする免疫賦活剤 |
| EP3929200B1 (de) | 2019-10-24 | 2023-12-27 | ASAI Germanium Research Institute Co., Ltd. | Neuartige organogermaniumverbindung |
-
1986
- 1986-03-10 JP JP61051687A patent/JPS62252793A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62252793A (ja) | 1987-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2568401B2 (ja) | 水溶性メグルミン塩及びグルカミン塩、その製造方法並びにこれを含有する医薬組成物 | |
| US4260769A (en) | 5,5-Diphenylhydantoins | |
| US20070098815A1 (en) | Orally Administrable Gallium Compositions and Methods of Use | |
| EP0154009B1 (de) | Verwendung von Thiazid-Diuretika zur Herstellung von nicht-diuretischen antihypertensiven Arzneimitteln | |
| KR20140123081A (ko) | 아미노산과 카르복실산을 포함한 게르마늄의 착체 및 이를 제조하는 방법 | |
| US4163058A (en) | Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof | |
| US4973553A (en) | Salt or organogermanium compound and medicine containing the same | |
| US4073895A (en) | Isopropylamino pyrimidine orthophosphate | |
| US5162344A (en) | Procaine double salt complexes | |
| EP0391971A1 (de) | Verbesserung der toxizitätskurven in der chemotherapie. | |
| JPS5989671A (ja) | ２，５−ピペラジンジオン誘導体 | |
| JPH0321558B2 (de) | ||
| US4151188A (en) | Arsenamide compound | |
| JPS6089488A (ja) | 新規アミノ酸誘導体の製法 | |
| CA1296277C (en) | Salt of organogermanium compound and medicine containing the same | |
| CA1132562A (en) | Halogeno derivatives of isopropylamino pyrimidine, their preparation and therapeutic use | |
| KR930007994B1 (ko) | 유기 게르마늄 화합물의 염 및 이를 포함하는 약제 | |
| US5002968A (en) | Activator for osteoblasts | |
| US3422191A (en) | Compositions and methods for tranquilization employing salts of n-morpholine ethanol | |
| US5254686A (en) | Procaine double salt complexes | |
| US3255190A (en) | Amine salts of pyrrolidone carboxylic acid | |
| SU1764654A1 (ru) | Средство дл лечени больных алкоголизмом | |
| RU2101011C1 (ru) | Средство, обладающее анальгетическим действием | |
| JPS6165819A (ja) | 有機ゲルマニウム化合物を含有する薬剤組成物 | |
| CA1301776C (en) | Compound of choline, a process for its preparation and therapeutic composition containing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |